Plasmid DNA Endotoxin Reduction via MDS Bacterial Hosts

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing plasmid DNA as therapeutic agents fail to completely eliminate endotoxins, particularly from bacterial hosts like E. coli, which are essential for viability and cannot be wholly deleted without being lethal, limiting the reduction of endotoxin levels in DNA preparations.

Innovation Solution

Utilizing multiple deletion strain (MDS) bacteria lacking genes involved in lipopolysaccharide and enteric common antigen production, such as msbB, to grow plasmid DNA, which reduces endotoxin levels through genetic means, thereby minimizing contaminants and improving purification efficiency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If standard bacterial strains (e.g., E. coli) are used to produce plasmid DNA, then robust growth and high DNA yield are achieved, but endotoxin levels remain high and cannot be completely eliminated

Engineering Contradiction:
Improveplasmid DNA yieldVSAvoidendotoxin levels
Core Design Contradiction:
ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent modifies the genetic parameters of the bacterial host by deleting specific genes (msbB, rfa, waa, bgaA) involved in lipopolysaccharide biosynthesis. This genetic parameter change fundamentally alters the bacterial cell's endotoxin production capability, reducing endotoxin levels by 1000-10000 fold while preserving the ability to support plasmid DNA replication and bacterial growth.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent extracts and removes specific harmful genetic elements (endotoxin biosynthesis genes) from the bacterial genome while retaining the essential functions needed for plasmid production. By selectively deleting genes responsible for LPS synthesis, the harmful endotoxin component is extracted from the system without compromising the overall productivity of plasmid DNA generation.

Inventive Principle:
Principle #2Taking out (Extraction)

2Object-generated harmful factors

If multiple gene deletions are performed to reduce endotoxin, then endotoxin levels decrease significantly, but bacterial viability and growth capacity may be compromised

Engineering Contradiction:
Improveendotoxin levelsVSAvoidbacterial viability
Core Design Contradiction:
Object-generated harmful factorsVSReliability

Solution Approach 1:

The patent applies local quality modification by specifically targeting and deleting only the genes responsible for endotoxin biosynthesis (msbB, rfa, waa, bgaA) while leaving the rest of the bacterial genome intact. This localized genetic modification ensures that essential functions for bacterial viability and plasmid production remain unchanged, while only the harmful endotoxin production is eliminated.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent converts the harmful effect of endotoxin production into a benefit by creating a bacterial strain that is inherently low-endotoxin or endotoxin-free. The deleted genes that previously caused harm (endotoxin-mediated immune responses and purification complications) are transformed into an advantage, producing plasmid DNA with dramatically reduced endotoxin contamination without requiring additional purification steps.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Ease of manufacture

If conventional purification methods are used, then plasmid DNA is recovered, but endotoxin contaminants remain in the final preparation

Engineering Contradiction:
Improvepurification processVSAvoidendotoxin contamination
Core Design Contradiction:
Ease of manufactureVSObject-generated harmful factors

Solution Approach 1:

The patent performs preliminary action by genetically modifying the bacterial host before plasmid DNA production to eliminate endotoxin biosynthesis capability. This preemptive genetic modification ensures that endotoxins are not produced during bacterial growth and plasmid replication, so the starting material for purification is already low-endotoxin, eliminating the need for specialized endotoxin removal steps.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The genetically modified bacterial strain serves itself by inherently producing low-endotoxin plasmid DNA through its altered metabolism. The bacteria's own genetic makeup (lacking endotoxin biosynthesis genes) automatically ensures that the plasmid DNA it produces is free from endotoxin contamination, without requiring external intervention or additional purification mechanisms.

Inventive Principle:
Principle #25Self-service

Data Source

PatentEP2027272B1Plasmid DNA preparations and methods for producing same
Publication Date: 2016.01.06 SCARAB GENOMICS LLC

AI summary

The various embodiments of the present invention relate generally to plasmid DNA preparations and to methods for producing and using such preparations.